Study determines how many patients hospitalized with COVID-19 had contraindications to nirmatrelvir–ritonavir and would have required an alternate outpatient treatment.
The National Association of Pharmacy Regulatory Authorities has finalized its recommendations on on brimonidine tartrate ophthalmic solution in concentrations up to and Including 0.025%.
Chief Medical Adviser Dr. Supriya Sharma says the first signs of supply issues arose in April but it wasn't until August that companies warned their efforts to increase supplies were failing.